

Curriculum vitae et studiorum

Paolo Rovero, born in Florence in 1958, is associate professor of pharmaceutical chemistry with the Medical School of the University of Florence. He graduated in chemistry from the University of Florence in 1983.

Since 1985, his research interests are related to the design, synthesis, conformational analysis and biological characterization of peptides of pharmaceutical, cosmeceutical, and biotechnological interest. He is coauthor of more than 240 scientific publications on international journals and of 22 patents of pharmaceutical relevance. H-index: 40 (WoS 15/02/2022). He is a member of the Italian Chemical Society, the Italian Peptide Society (Treasurer), the European Peptide Society, and the American Peptide Society (charter member).

April 1985 – March 1986: research fellow in the laboratory of Professor D. Regoli, Dept. of Pharmacology, Medical School, University of Sherbrooke, Canada.

April 1986 – May 1991: scientist in charge of the Peptide Synthesis Laboratory of the Research Department of Industrie Farmaceutiche A. Menarini, in Florence, Italy.

June 1991 – October 1998: researcher at the Institute of Mutagenesis and Differentiation of the National Research Council (CNR) in Pisa, Italy.

November 1998 – October 2003: associate professor of pharmaceutical chemistry with the School of Pharmacy of the University of Salerno, Italy.

From November 2003: moves to the University of Florence. Co-founder of the Interdepartmental Laboratory of Chemistry and Biology of Peptides and Proteins (PeptLab; www.peptlab.unifi.it). Strongly involved in technology transfer, in 2003 founded the first academic spin-off company of the University of Florence, **EspiKem Srl** (www.espikem.com), a Contract Research Organization, recently specialized in the development of bioactive peptides of cosmeceutical interest. In 2007 was among the academic founders of a research company (**Toscana Biomarkers Srl**), capitalized by Tuscan institutional funds and incubated by the Toscana Life Sciences Foundation incubator in Siena.

February 2022